Immunotherapy for Lung Cancer Can Trigger Type 1 Diabetes: What Patients Should Know

Pembrolizumab is a type of immunotherapy that helps the body's immune system fight certain cancers, including non-small cell lung cancer. It works by targeting a protein called PD-1 that normally acts as a 'brake' on immune cells, allowing tumors to hide. By releasing that brake, the drug can help the immune system recognize and destroy cancer cells.

However, this approach carries a trade-off. By boosting immune activity, pembrolizumab can sometimes trigger the immune system to attack the body's own tissues—a problem called immune-related adverse events, or irAEs. While many irAEs are manageable, some can be serious, affecting organs like the pancreas and thyroid.

Doctors recently documented a case of a 62-year-old man being treated with pembrolizumab for lung cancer who developed sudden symptoms of high blood sugar: excessive thirst, frequent urination, and weakness. He was diagnosed with diabetic ketoacidosis (DKA), a dangerous condition where the body produces too much acid and blood sugar becomes critically high.

Blood tests showed that his pancreas had essentially stopped producing insulin, and antibody testing ruled out other causes. The pattern was consistent with immune checkpoint inhibitor-induced Type 1 diabetes—meaning the immunotherapy had triggered an autoimmune attack on the insulin-producing cells in his pancreas. At the same time, the patient also developed thyroid problems with signs of autoimmune thyroiditis.

This case is notable because the patient had no prior personal or family history of autoimmune disease, which doctors might otherwise have flagged as a risk factor. It demonstrates that immunotherapy-triggered Type 1 diabetes can occur unexpectedly, even in patients who seem at lower risk.

The severity and speed of onset—progressing to diabetic ketoacidosis—underscores why early detection is critical. When Type 1 diabetes develops suddenly as an immune side effect, the body's insulin production can drop very rapidly.

Doctors emphasize that patients starting pembrolizumab or similar immunotherapies should have baseline blood tests to check pancreatic and thyroid function before treatment begins. Regular monitoring during and after treatment is also important.

Patients should be educated about warning signs of diabetes—including increased thirst, frequent urination, fatigue, and blurred vision—and report these symptoms to their medical team right away. Because immunotherapy-induced endocrine problems can affect multiple glands, coordinated care involving oncologists, endocrinologists, and other specialists offers the best chance of catching and managing complications early.

This case reinforces that even patients without a history of autoimmune disease need vigilant monitoring, and that a high index of suspicion among clinicians can help prevent severe outcomes like diabetic ketoacidosis.

Source: Cureus. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.